Literature DB >> 20646002

NOD2 polymorphisms in clinical phenotypes of common variable immunodeficiency disorders.

K Packwood1, E Drewe, E Staples, D Webster, T Witte, J Litzman, W Egner, R Sargur, W Sewell, E Lopez-Granados, S L Seneviratne, R J Powell, B L Ferry, H M Chapel.   

Abstract

Common variable immunodeficiency disorders (CVIDs) are a heterogeneous group of diseases characterized by hypogammaglobulinaemia and consequent susceptibility to infection. CVID patients commonly develop a variety of additional manifestations for which the causative factors are not fully understood. Two such manifestations are granulomatous disease and enteropathy. Because the ability to predict complications would aid clinical management, we continue to search for possible disease modifier genes. NOD2 acts a microbial sensor and is involved in proinflammatory signalling. Particular mutations of the NOD2 gene are associated with Crohn's disease including gly908arg, leu1007finsc and arg702trp polymorphisms. We hypothesized that NOD2 polymorphisms may be a disease modifier gene towards an enteropathic or granulomatous phenotype within CVIDs. Sequence-specific primers returned genotypes for 285 CVID patients from centres across the United Kingdom and Europe. We present the frequencies of the different phenotypes of patients within our international cohort. Arg702trp polymorphisms were significantly less frequent than wild-type (WT) (P = 0·038) among international CVID patients with splenomegaly. Gly908arg polymorphisms were more prevalent than WT in UK patients with autoimmune disorders (P = 0·049) or enteropathy (P = 0·049). NOD2 polymorphisms were not more prevalent than WT in CVID patients with clinical phenotypes of granulomata. UK allele frequencies of 0·014, 0·056 and 0·026 were found for gly908arg, arg702trp and leu1007finsc NOD2 polymorphisms, respectively. These do not differ significantly from UK immunocompetent controls confirming, as expected, that in addition these NOD2 polymorphisms do not confer susceptibility to CVIDs per se.
© 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20646002      PMCID: PMC2962972          DOI: 10.1111/j.1365-2249.2010.04216.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

1.  CARD15 mutations in Blau syndrome.

Authors:  C Miceli-Richard; S Lesage; M Rybojad; A M Prieur; S Manouvrier-Hanu; R Häfner; M Chamaillard; H Zouali; G Thomas; J P Hugot
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

2.  Dysbiosis in inflammatory bowel disease.

Authors:  C P Tamboli; C Neut; P Desreumaux; J F Colombel
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

3.  Tumor necrosis factor production by human sarcoid alveolar macrophages.

Authors:  P R Bachwich; J P Lynch; J Larrick; M Spengler; S L Kunkel
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

4.  NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.

Authors:  J Wehkamp; J Harder; M Weichenthal; M Schwab; E Schäffeler; M Schlee; K R Herrlinger; A Stallmach; F Noack; P Fritz; J M Schröder; C L Bevins; K Fellermann; E F Stange
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

5.  Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis.

Authors:  G W Hunninghake
Journal:  Am Rev Respir Dis       Date:  1984-04

6.  Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation.

Authors:  Ernst Holler; Gerhard Rogler; Hans Herfarth; Julia Brenmoehl; Peter Johannes Wild; Joachim Hahn; Günther Eissner; Jürgen Schölmerich; Reinhard Andreesen
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

7.  NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Warren Strober
Journal:  Nat Immunol       Date:  2004-06-27       Impact factor: 25.606

8.  Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis.

Authors:  B W Robinson; T L McLemore; R G Crystal
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

9.  Compartmentalized activation of the interleukin 2 gene by lung T lymphocytes in active pulmonary sarcoidosis.

Authors:  J Müller-Quernheim; C Saltini; P Sondermeyer; R G Crystal
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

10.  Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae.

Authors:  Bastian Opitz; Anja Püschel; Bernd Schmeck; Andreas C Hocke; Simone Rosseau; Sven Hammerschmidt; Ralf R Schumann; Norbert Suttorp; Stefan Hippenstiel
Journal:  J Biol Chem       Date:  2004-06-23       Impact factor: 5.157

View more
  2 in total

1.  Increased prevalence of gastrointestinal viruses and diminished secretory immunoglobulin a levels in antibody deficiencies.

Authors:  A A J M van de Ven; W J M Janssen; L S Schulz; A M van Loon; K Voorkamp; E A M Sanders; J G Kusters; S Nierkens; M Boes; A M J Wensing; J M van Montfrans
Journal:  J Clin Immunol       Date:  2014-08-19       Impact factor: 8.317

Review 2.  Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin.

Authors:  Lei Qin; Nian Liu; Chao-le-Meng Bao; Da-Zhi Yang; Gui-Xing Ma; Wei-Hong Yi; Guo-Zhi Xiao; Hui-Ling Cao
Journal:  Acta Pharmacol Sin       Date:  2022-07-27       Impact factor: 7.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.